Advertisement

Topics

Triumvira Immunologics, Inc. Company Profile

12:41 EST 12th November 2018 | BioPortfolio

Triumvira Immunologics, Inc. (“Triumvira”) is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., with the vision of developing novel T cell therapies that are safer and more efficacious than current gene therapy cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Our proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the Major Histocompatibility Complex (MHC), allowing for the development of better therapies for a broader range of patients with solid or liquid malignancies and with diseases other than cancer. With operations spanning North America, our corporate offices are located in Austin, Texas, with our research facilities in Hamilton, Ontario. For more information, visit www.triumvira.com or send email inquiries to partners@triumvira.com


News Articles [16 Associated News Articles listed on BioPortfolio]

Triumvira Immunologics Names Donna Rill Chief Technology Officer

Triumvira Immunologics, an Austin, TX-based biotech, appointed Donna Rill to serve as chief technology officer. Triumvera said Rill will use her technology development and manufacturing experience to ...

Triumvira licenses antibodies from University of Toronto

The University of Toronto granted Triumvira Immunologics Inc. exclusive rights to antibodies for use in the development of T-cell therapeutics for cancer.

Triumvira Immunologics Appoints Scott Smith to Board of Directors

Innovative immuno-therapy company welcomes former President and COO of Celgene Triumvira Immunologics, Inc., a privately held biopharmaceutical company developin...

Triumvira Hires Donna Rill as Chief Technology Officer

Brings 30-years of Experience to Company’s Technology Development and Manufacturing Operations Triumvira Immunologics, a privately held biopharmaceutical company deve...

Triumvira Immunologics to Participate in Two Upcoming Conferences: Sachs Immuno-Oncology BD&L and Investment Forum and 2018 BIO International Convention

Triumvira Immunologics, Inc., a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack multiple types of cancers, today anno...

CCAB And Triumvira Immunologics Announce Triumvira’s License Agreement with University of Toronto for the Discovery of Antibody Drug Development Candidates

The Centre for the Commercialization of Antibodies and Biologics (CCAB) and Triumvira Immunologics, Inc. (Triumvira), announced today a new licensing agreement between the

Triumvira Expands Management Team with Chief Medical Officer and VP of Finance

Innovative immuno-therapy company welcomes proven leaders in pharma and therapeutics Triumvira Immunologics, a privately held biopharmaceutical company developing ...

Triumvira Immunologics to Present at Two Upcoming Conferences: International Society for Cellular Therapy and Bloom Burton & Co. Healthcare Investor Conference

Triumvira Immunologics, Inc., a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack multiple types of cancers, today anno...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [5 Associated Companies listed on BioPortfolio]

Triumvira Immunologics, Inc.

Triumvira Immunologics, Inc. (“Triumvira”) is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., with the...

Triumvira Immunologics

Triumvira is developing an engineered T-cell technology called the T-Cell Antigen Coupler (TAC), developed in the laboratory of Dr. Jonathan Bramson at McMaster University in Hami...

Signature Immunologics

Signature Immunologics produces anti-hapten IgGs for High Performance Immunocytochemistry (HPI), targeting key small molecules in cell physiology, including fast neurotransmitter amino acids and pivot...

Quantum Immunologics, Inc.

Signature Immunologics, Inc.

Nil

More Information about "Triumvira Immunologics, Inc." on BioPortfolio

We have published hundreds of Triumvira Immunologics, Inc. news stories on BioPortfolio along with dozens of Triumvira Immunologics, Inc. Clinical Trials and PubMed Articles about Triumvira Immunologics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Triumvira Immunologics, Inc. Companies in our database. You can also find out about relevant Triumvira Immunologics, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record